ALNY News and Press, Alnylam Pharmaceuticals Inc. From 04/27/22

Alnylam Pharmaceuticals (NASDAQ:ALNY) is scheduled to announce Q1 earnings results on Thursday, April 28th, before market open. The consensus EPS Estimate is -$1.46 (+11.0% Y/Y) and the consensus Revenue Estimate is $242.82M (+36.7% Y/Y). Over the last 2 years, ALNY has beaten EPS estimates 0...

Morgan Stanley downgraded biopharma company Alnylam (NASDAQ:ALNY) to Equal Weight from Overweight in a research note issued on Monday. The firm's price target dropped to $178 from $210, still implying a potential upside of 11% from stock's last close. ALNY share price is down 5% in early...

John Maraganore and Tassos Gianakakos, the former CEOs of, respectively, Alnylam Pharmaceuticals (ALNY) and MyoKardia, are joining Evelo Biosciences (NASDAQ:EVLO) as strategic advisors. Maraganore was Alnylam's founding CEO and just left the company last year, while Gianakakos served as MyoKa...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Alnylam ( ALNY ): pioneering a new class of therapeutics based on RNA interference and a better fit for collaboration partner Novartis (NYSE: NVS ) BioMarin (NASDAQ: BMRN ): a rare disease gene therapy ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2022 on Thursday, April 28, 2022, before the U.S. financial markets open. Management will provide an ...

Alnylam Pharmaceuticals (NASDAQ:ALNY) stock rose April 12 after H.C. Wainwright raised its price target on the company to $400 from $350. Analyst Patrick Trucchio also reiterated a Buy rating on the shares. The analyst is more positive on Alnylam's TTR franchise. Trucchio words echoed Alnylam...

Goldman Sachs equity strategists stressed the importance of pricing power for companies given a four-decade high in inflation and rising commodities prices. "Pricing power will become increasingly important in the face of continued inflation and cost pressures," David Kostin, chief U.S. equit...

Alnylam specializes in commercialized and in-pipeline RNA interference (RNAi) therapeutics. Sarepta’s commercial portfolio focuses on Duchenne muscular dystrophy (DMD), a genetic disorder of progressive muscular weakness, typically in young boys. BioMarin is a commercial st...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced that Steven Paul, M.D. is retiring from the Board of Directors effective April 16, 2022. Dr. Paul has served as a member of the Alnylam Board of Directors since September 2010. He brou...

H.C. Wainwright urges investors to buy Alnylam Pharma (NASDAQ:ALNY) on the dip after the shares of the commercial-stage biotech dropped on Monday in reaction to a delay in the U.S. regulatory review for vutrisiran, an experimental therapy for transthyretin-mediated amyloidosis (ATTR-PN). The ...